Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

ith non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several research molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 27, 2014 Scientists, researchers, ... for SPIE Laser Damage 2014 symposium. Marking ... for high-power lasers will run 14-17 September. The event ... optics and photonics . , The premier conference for ... laser damage to optical materials will engage researchers and ...
(Date:8/28/2014)... San Diego, CA (PRWEB) August 28, 2014 ... products, Pipette.com is offering a promotion for ... enables Pipette.com customers to purchase the highest quality ... Centrifuge Tubes are ideal for customers doing chemical, ... benefit lab technicians who are not regularly able ...
(Date:8/27/2014)... 2014 Rhythm, a biopharmaceutical company developing peptide ... result in metabolic disorders, announced today that it has ... U.S. Securities and Exchange Commission (SEC) relating to the ... stock. The number of shares to be offered and ... been determined. Citigroup and Cowen and Company ...
(Date:8/27/2014)... of nature,s mysteries is how plants survive impact ... the sun,s rays, while using this energy for ... in the plant,s blades quickly dissipate the energy ... quakes. Researchers at DTU Physics have now managed ... algae and bacteria contain light-absorbing proteins which play ...
Breaking Biology Technology:Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2DTU researchers film protein quake for the first time 2
... SAN DIEGO , April 22 Neurocrine Biosciences, Inc. (Nasdaq: ... 2010 financial results after the Nasdaq market closes on Wednesday, April 28, ... discuss its financial results and provide a Company update Thursday morning, April ... Pacific Time ). , , , ...
... 22 As evidence of its drive to ... activity, Smith & Nephew ( SNN, LSE: SN) Orthopaedics ... its VERILAST technology for knee replacement implants. After simulating ... knee replacement, VERILAST technology produced an 81-percent reduction* in ...
... , April 22 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... 29 at 4:30 p.m. Eastern Time to discuss its financial results for ... quarter financial results after market close. , , ... , , , ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results 2Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 2Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 3Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 4Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 5PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010 2
(Date:8/28/2014)... his collaborators have developed an online analytic tool that ... cells for biomedical investigation. CellNet is a free-use Internet ... cell engineering. Details of CellNet and its application to ... in the journal Cell . , "This free ... types of cell-based investigations and can potentially offer help ...
(Date:8/28/2014)... 2014  Privacy Advocate and Senior Staff Attorney at ... joins the lineup of biometric and mobile commerce experts ... Executive Summit in Tampa, Florida ... speakers include Steven Rahman, Director, Technology and Strategy at Samsung, ... The theme of this year,s event is Mobility at ...
(Date:8/28/2014)... August 28, 2014 Dyslexia, the most commonly ... a neurological reading disability that occurs when the ... don,t function normally. , The use of non-invasive ... activity is disrupted in dyslexia. However, most prior ... of brain regions, leaving a gap in our ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2Dyslexic readers have disrupted network connections in the brain 2
... have found that two genes already known to control ... They report their findings in the April issue of ... genes are required for a dividing cell's halves to ... be helpful in stopping the uncontrolled cell division found ...
... inflammation is linked to the development of certain ... premalignancy are not well understood. A new research ... Cell identifies B lymphocytes as important regulators of ... that drugs targeted against B lymphocytes or recruitment ...
... from Columbia University Medical Center have shown that a ... arteries during a heart attack does not improve patient ... commonly and successfully used during angioplasty in vein grafts ... the March 2 issue of the Journal of the ...
Cached Biology News:Pair of cancer genes found to drive both cell migration and division 2B cells are required for development of epithelial cancer associated with chronic inflammation 2Columbia study shows widely used artery clearing device does not help patients during heart attack 2
... polyclonal to Ki67 - Proliferation Marker, prediluted ... cycle related nuclear protein, expressed by proliferating ... cell cycle (G1, S, G2 and M ... cells. Ki67 antibodies are useful in establishing ...
UBC13 Antibody...
Request Info...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Biology Products: